Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Mar 22;37(26):3485–3500. doi: 10.1038/s41388-018-0161-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

PMC Copyright notice

Fig. 2 — CREPT gene was amplified in CRC. a Significant genomic alterations of chromosome 20p13-q13 across 12 while blue color refers to copy number loss. Red box indicates the location of CREPT gene. BLCA bladder urothelial carcinoma, BRCA breast invasive carcinoma, KIRC kidney renal clear cell carcinoma, COAD colorectal adenocarcinoma, GBM glioblastoma multiformed, HNSC head and neck squamous cell carcinoma, LAML acute myeloid leukemia, LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, READ rectum adenocarcinoma, OV ovarian serous cystadenocarcinoma, UCEC uterine corpus endometrioid carcinoma. b DNA copy number variation of CREPT was found in 48.28% (56/116) CRC cases by real-time PCR with a Taqman probe targeting CREPT. c The correlation between copy number changes of CREPT and mRNA overexpression (R = 0.485, P < 0.0001)